What is the best trade option for X4 Pharmaceuticals Inc (XFOR) stock?

X4 Pharmaceuticals Inc [XFOR] stock is trading at $0.81, up 38.91%. An important factor to consider is whether the stock is rising or falling in short-term value. The XFOR shares have gain 25.67% over the last week, with a monthly amount glided 140.08%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

X4 Pharmaceuticals Inc [NASDAQ: XFOR] stock has seen the most recent analyst activity on December 12, 2023, when B. Riley Securities downgraded its rating to a Neutral and also revised its price target to $1 from $3. On December 22, 2022, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $3 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $3 on December 12, 2022. Oppenheimer initiated its recommendation with a Outperform and recommended $20 as its price target on December 23, 2019. ROTH Capital started tracking with a Buy rating for this stock on December 18, 2019, and assigned it a price target of $20. In a note dated December 09, 2019, Citigroup upgraded an Buy rating on this stock and boosted its target price from $16 to $20.

X4 Pharmaceuticals Inc [XFOR] stock has fluctuated between $0.26 and $1.60 over the past year. Currently, Wall Street analysts expect the stock to reach $3.67 within the next 12 months. X4 Pharmaceuticals Inc [NASDAQ: XFOR] shares were valued at $0.81 at the most recent close of the market. An investor can expect a potential return of 353.09% based on the average XFOR price forecast.

Analyzing the XFOR fundamentals

Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -6.19%, Pretax Profit Margin comes in at -3.99%, and Net Profit Margin reading is -4.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.33 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.28.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6564 points at the first support level, and at 0.5070 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8987, and for the 2nd resistance point, it is at 0.9916.

Ratios To Look Out For

For context, X4 Pharmaceuticals Inc’s Current Ratio is 4.89. On the other hand, the Quick Ratio is 4.80, and the Cash Ratio is 3.33. Considering the valuation of this stock, the price to sales ratio is 122.69, the price to book ratio is 2.28.

Transactions by insiders

Recent insider trading involved Ragan Paula, President and CEO, that happened on Nov 15 ’24 when 31897.0 shares were sold. Officer, Ragan Paula completed a deal on Nov 15 ’24 to buy 31897.0 shares. Meanwhile, President and CEO Ragan Paula sold 31897.0 shares on Oct 15 ’24.

Related Posts